Why the study?
Does inhibition of Ang1 expression by antisense RNA reduce tumor growth and angiogenesis in immunodeficient mice with HeLa cell xenografts?
Does inhibition of Ang1 expression by antisense RNA reduce tumor growth and angiogenesis in immunodeficient mice with HeLa cell xenografts?
Inhibition of Ang1 expression via antisense RNA effectively controls tumor growth by inhibiting tumor angiogenesis in a preclinical xenograft model.
Answers are grounded in this paper and cite their sources.
Ang1 inhibition merits further preclinical testing as an anti-angiogenic strategy; leaves open translation to clinical oncology.
Angiopoietin-1 (Ang1) is an angiogenic growth factor that functions through activation of its endothelium-specific tyrosine kinase receptor Tie2; it mediates the interaction between endothelial and surrounding cells to promote the remodeling, maturation and stabilization of blood vessels. Although Ang1 is expressed constitutively in many adult tissues, its role in tumor growth and metastasis is not clear. Here we describe experiments in which Ang1 expression was inhibited in HeLa cells by an antisense RNA approach. The modified HeLa cells produced significantly less Ang1 protein both in cultured cells and in tumors formed when these cells were injected into immunodeficient mice. The Ang1 antisense tumors grew much more slowly, with significantly reduced tumor angiogenesis compared with control tumors. Furthermore, they also had substantially increased tumor cell apoptosis and decreased tumor necrosis. Our results indicate that the perturbation of Ang1 expression in tumors could be an effective method to control tumor growth by inhibiting tumor angiogenesis and that antisense RNA is an efficient way to inhibit Ang1 protein production in tumor cells.
No takes yet. Share an insight, caveat, or question.
Shim et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: